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ABSTRACT
Introduction: As part of the CEPHEUS study,
CEPHEUS I was conducted in 2010 and 2011 in
Cairo and then the CEPHEUS II study was car-
ried out in Alexandria and Delta Regions in
Egypt between April 2014 and August 2015 to
determine the proportion of dyslipidemic
patients on lipid-lowering treatment reaching
LDL-C treatment goals.
Methods: We conducted an open-label, obser-
vational, multicenter, cross-sectional survey
where 90 investigators enrolled 1127 patients
receiving lipid-lowering drugs for at least
3 months. After signing informed consent
forms, the study questionnaires were completed
by patients and investigators. Blood samples
were taken for laboratory investigations.
Patients with missing LDL-C data were excluded
from the analysis and results from 896 patients
were analyzed according to European
Atherosclerosis Society and EAS/ESC 2011
guidelines.
Results: Out of 896 patients enrolled based on
the risk stratification of EAS/ESC 2011 guideli-
nes, 12.4% were classified as low risk, 20.0% as
moderate risk, 2.5% as high risk, and 65.2% as
very high risk. Achievement goals were 84.7,
44.7, 18.2, and 22.3% for low-risk, moder-
ate-risk, high-risk, and very high risk patients,
respectively, with an overall achievement goal
of 34.4%. The study population included 50.2%
diabetes, 64.4% hypertension, 54.9% metabolic
syndrome, 32.2% family history of cardiovas-
cular disease, 23.1% smokers, and 33.8% sec-
ondary prevention. Lipid-lowering agents were
prescribed as a monotherapy to 90.1% and in
combination in 9.9% with goal achievements of
34 and 38%, respectively (p[0.05). Statins were
prescribed to 86.9% of patients. The most fre-
quent prescribed statins were rosuvastatin
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(47.1%) and atorvastatin (36.0%), followed by
simvastatin (9.2%). Treatment goal was
achieved in 34.2, 36.0, and 31.7% for rosuvas-
tatin, atorvastatin, and simvastatin, respec-
tively, with no significant difference in
achievement goals (p[0.05).
Conclusions: Hypercholesterolemia is still not
being effectively managed in many at-risk
patients in Egypt. The majority of patients
enrolled in the study were being actively treated
with lipid-lowering medications yet the per-
centage goal achievement was less when com-
pared to CEPHEUS results.
Keywords: Cardiovascular; CVD;
Cardiovascular risk; CEPHEUS; Egypt;
Hypercholesterolemia; Statins
INTRODUCTION
Cardiovascular diseases (CVD) are the leading
cause of death worldwide. Multiple risk factors
contribute to CVD. A recent standardized
case–control study in 52 countries specifically
focusing on acute myocardial infarction iden-
tified that six risk factors (dyslipidemia, smok-
ing, hypertension, diabetes mellitus, abdominal
obesity, and stressful psychosocial factors)
account for 90% of myocardial infarctions in
men and 94% in women [1].
Epidemiological surveys have shown that
elevated total serum cholesterol (TC) and par-
ticular elevated low-density lipoprotein choles-
terol (LDL-C) levels are strongly correlated with
CHD risk. Many guidelines identify LDL-C as
the primary target of cholesterol-lowering
therapy and recommend LDL-C goals either
numerical or percentage of reduction that are
based on the risk category a patient belongs to
[2, 3].
Hypercholesterolemia treatment has shown
clear benefits in the primary and secondary
prevention of CVD. However, cross-sectional
surveys conducted in Europe [5, 6], and the USA
[6–8] on the management of risk factors in
patients with CHD have indicated that hyperc-
holesterolemia continues to be inadequately
treated [4–6]. Accordingly, many studies are
required to assess the current level of
under-treatment of hypercholesterolemia,
defined as receiving lipid-lowering drug therapy
but having uncontrolled TC and/or LDL-C
levels and to understand better why patients on
pharmacological treatment do not achieve their
treatment goals [4–7].
This study is part of the worldwide con-
ducted CEPHEUS studies; Centralized Pan-Mid-
dle East Survey on the under-treatment of
hypercholesterolemia and the second wave of
the Centralized Pan-Middle East Survey on the
under-treatment of hypercholesterolemia:
results from the CEPHEUS Study in Egypt [8].
The current study is based on the European
Atherosclerosis Society 2011 and the European
Society of Cardiology guidelines (EAS/ESC 2011)
[8]. The primary objective is to determine the
proportion of patients on lipid-lowering phar-
macological treatment reaching the LDL-C
goals in Egypt according to the EAS/ESC 2011
guidelines. Secondary objectives were to deter-
mine the proportions in pre-defined subpopu-
lations including primary and secondary
prevention, metabolic syndrome, patients’ risk
profile category, and identification of determi-
nants (patient and physician characteristics) for
patients not reaching their treatment goals and
physician characteristics associated with the
allocation of different treatment regimens.
METHODS
This is an open-label, observational, non-inter-
ventional, multicenter, single-visit cross-sec-
tional survey conducted on patients under
lipid-lowering pharmacological treatment.
Ninety investigators enrolled 1127 patients on
lipid-lowering drugs between April 24, 2014 and
August 29, 2015 from Alexandria and Delta
Regions in Egypt as part of the CEPHEUS study
(NIS-EG-CRE-2012/01). Patients of age 18 years
or more receiving lipid-lowering drug for at
least 3 months with no dose change for at least
6 weeks signed informed consent to participate
and comply with study procedures. Before
assessment, after signing informed patient
consent, the study questionnaires were com-
pleted by patients and investigators. The inves-
tigators completed case record forms (CRF) with
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the patient’s demographics, known cardiovas-
cular risk factors, cardiovascular medical his-
tory, current lipid-lowering drug treatment, and
the reason for the current therapy. Samples
were taken for total cholesterol, LDL choles-
terol, HDL cholesterol, triglycerides, HbA1c,
and the ratio of total cholesterol/HDL-C was
calculated. The investigators received results
within 5 days and completed the CRFs.
Under-treatment was defined as receiving
lipid-lowering pharmacological treatment and
not reaching the LDL-C goals according to the
EAS/ESC 2011 guidelines. Non-HDL-C goals was
defined as patients with HDL-c\40 mg/dl and
fasting triglycerides[200 mg/dl.
Among the 1127 enrolled patients, patients
with missed LDL-C data (n = 231) were exclu-
ded from the analysis and results from 896
patients are presented here.
Statistical Analysis
Data of 896 subjects were analyzed in this study.
This gives a margin error of ±3.2% at 95%
confidence level with expected number of
patients achieving treatment goals at 50%.
Number and percentage (n and %) presented
the categorical data and Chi-square test (or its
subsidiaries) was used to obtain p values to test
significance for difference between groups.
Descriptive statistics (mean ± SD) presented the
numerical data and Student’s t test (or its sub-
sidiaries) was used to obtain p values to test
significance for difference between groups. The
calculation of statistics and proportions did not
include the missing data. Missing values were
presented in separate tables.
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation (insti-
tutional and national) and with the Helsinki
Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
RESULTS
Eight hundred ninety-six subjects were included
in the analysis. The mean age was
53.9 ± 10.7 years and 57.6% were male. The
main reason of pharmacological therapy was for
primary prevention with 59.4% of patients.
Statins were the most prescribed agents with
95.2% (853 of 896) of patients; 90% (768) used
statins as monotherapy and 10% (85) in com-
bined therapy. Rosuvastatin was the most fre-
quently prescribed statin. It was prescribed to
47.1% (422 of 896) from which 391 were
monotherapy and 31 were combined therapy.
Other and more detailed demographic data and
patients characteristics are shown in Table 1.
LDL Target Goal Achievement
Overall, 34.4% (308 of 896 patients) achieved
their LDL-C target goal according to the EAS/
ESC 2011 guidelines.
A total of 84.7% of low-risk patients achieved
target LDL-C goal (\155 mg/dl), 44.7% of
moderate-risk patients achieved target LDL-C
goal (\115 mg/dl), 18.2% of high-risk patients
achieved target LDL-C goal (\100 mg/dl) and
22.3% of very high risk patients achieved target
LDL-C goal (\70 mg/dl or C50% reduction).
From the patients who were on rosuvastatin,
33.2% reached the goal with monotherapy and
48.4% with combined therapy, with an overall
achievement of 34.2%. From patients who were
prescribed treatment for primary prevention:
36.1% achieved LDL-C goal, for secondary pre-
vention 29.9%, and familial hypercholes-
terolemia 36.2%. (p = 0.082). For special
populations, the goal was reached for 67.7% of
patients with metabolic syndrome and 63.1%
without (p = 0.087); the goal was reached for
21.6% of patients with diabetes mellitus and
46.5% without (p\0.001), and finally, goal was
reached for 29.6% of patients with arterial
hypertension and 42.6% without (p\0.001)
(Tables 2, 3).
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Table 1 Patients’ demography and other variables at the baseline visit
Parameter Variable Valid answer
(base)
Missing Mean and SD
or N and %
Age 896 0 53.9 10.7
Weight 892 4 92.3 17.1
Height 887 9 168.8 8.8
BMI 887 9 32.5 6.4
Waist circumference 857 39 99.5 21.3
Systolic BP 893 3 133.9 15.9
Diastolic BP 893 3 84.4 9.1
Gender Male, n (%) 896 0 516 57.6%
Female, n (%) 380 42.4%
Nationality Egyptian, n (%) 896 31 859 99.3%
Other (Syrian), n (%) 6 0.7%
Ethnicity Middle Eastern (including North
Africa)
869 27 857 98.6%
Caucasian (including Europe and
North America)
6 0.7%
Other, n (%) 6 0.7%
Reason for
pharmacological therapy
Primary prevention 876 20 520 59.4%
Secondary prevention 296 33.8%
Familial hypercholesterolemia 60 6.8%
Medical history History of coronary heart disease,
n (%)
896 0 309 34.5%
History of peripheral artery disease,
n (%)
894 2 118 13.2%
Cerebrovascular atherosclerotic
disease, n (%)
896 0 62 6.9%
Established CVD 886 10 376 42.4%
Comorbid condition Arterial hypertension, n (%) 871 25 561 64.4%
Diabetes, n (%) 877 19 440 50.2%
Family history of premature
cardiovascular disease, n (%)
845 51 272 32.2%
Current smoker, n (%) 872 10 207 23.1%
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Results of the Investigators’ Questionnaire
There were 41.4% of the investigators that
mentioned that they use EAS/ESC 2011 guide-
lines. Most of the investigators use guidelines to
set individual cholesterol targets; 94.4% depend
on LDL-C as an indicator.
Percent split of prescriptions as reported by
investigators was 86.9% for statins, 9.5% for
fibrates, and 3.6% for bile acid sequestrants and
other drugs. Investigators review their patients
mostly every 3 months, and they stated that an
average of 55.6% of patients achieved their target
cholesterol level. Detailed results of the investi-
gators’ questionnaire are presented in Table 4.
Table 1 continued
Parameter Variable Valid answer
(base)
Missing Mean and SD
or N and %
Lab test Total cholesterol, mg/dl (mmol/l) 896 0 189.3 47.6
HDL-C, mg/dl (mmol/l) 896 0 45.2 13
LDL-C, mg/dl (mmol/l) 896 0 115 41.7
Triglycerides, mg/dl (mmol/l) 894 2 150.9 84
Total cholesterol/HDL-C ratio 2 894 5 1.4
Glucose, mg/l 716 180 131.9 61.1
HbA1c, % (mmol/mol) 891 5 7.1 1.9
Current prescribed
medication groups
Statin monotherapy 885 11 768 85.7%
Statin ? ﬁbrate 47 5.2%
Statin ? ezetimibe 35 3.9%
Ezetimibe monotherapy 25 2.8%
Fibrate monotherapy 7 0.8%
Statin ? ﬁbrate ? ezetimibe 3 0.3%
Current prescribed
monotherapy drugs










Undeﬁned statins 32 3.6%
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Table 2 EAS/ESC 2011 risk-proﬁle category, number and percent in each group, lipid-lowering drug, mean and SD of the




Agent Dose Achieved treatment goal
Base % Name Base Mean SD N %
All 896 Rosuvastatin 442 14.6 5.1 152 34.4
Atorvastatin 323 24.8 14.8 118 36.5
Simvastatin 82 25.7 16.2 26 31.7
Ezetimibe 63 15.0 7.1 26 41.3
Fenoﬁbrate 56 260.0 64.8 21 37.5
Fluvastatin 10 10.0 1 10.0
Pravastatin 3 20.0 1 33.3
Lovastatin 3 40.0 1 33.3
Bezaﬁbrate 1 0 0.0
Gemﬁbrozil 1 0 0.0
Undeﬁned statin 32 21.1 11.7 9 28.1
Very high risk 584 65.2% Rosuvastatin 272 16.3 5.2 56 20.6
Atorvastatin 215 25.1 14.2 57 26.5
Simvastatin 52 31.0 20.2 10 19.2
Ezetimibe 40 14.2 5.1 12 30.0
Fenoﬁbrate 33 253.3 70.0 9 27.3
Fluvastatin 8 0 0.0
Pravastatin 2 20.0 1 50.0
Lovastatin 1 0 0.0
Bezaﬁbrate 1 0 0.0
Gemﬁbrozil 1 0 0.0
Undeﬁned statin 22 26.7 11.5 3 13.6
High risk 22 2.5% Rosuvastatin 11 15.0 7.1 2 18.2
Atorvastatin 7 15.0 7.1 2 28.6
Fenoﬁbrate 3 300.0 1 33.3
Simvastatin 2 0 0.0
Ezetimibe 2 0 0.0
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Results of the Patients’ Questionnaire
Eight hundred ninety-two patients returned
completed questionnaires. More than 75% of the
patients were aware of good and bad cholesterol
and mentioned that their doctor told them
about their level of cholesterol and target goals
and discussed the proper lifestyle, diet, and pre-
scribed medications; 78.5% mentioned that they
were satisfied with the information they had
about high cholesterol. Results showed that
patients were trying to take drugs as they were
prescribed but 41% mentioned that they some-
times forgot to take the tablet every day. Most of
the patients reported that they did not change
the drug they take and few of them (3.3%)
reported that they had changed the prescribed
drug more than two times. Of the patients, 49%
stated that they achieved their target cholesterol
level and 75% were satisfied with the treatment
they were taking. A strong correlation was found
between achieving treatment goal as obtained
from CEPHEUS II results and patient compliance
as obtained from patients’ questionnaire
(p\0.001). Table 5 shows detailed results of the
patients’ questionnaire.
DISCUSSION
CEPHEUS surveys in different countries world-
wide have aimed to investigate the proportion of





Agent Dose Achieved treatment goal
Base % Name Base Mean SD N %
Moderate risk 179 20.0% Rosuvastatin 88 13.4 4.8 47 53.4
Atorvastatin 61 23.5 11.9 23 37.7
Simvastatin 16 23.3 15.3 3 18.8
Ezetimibe 15 17.5 10.4 8 53.3
Fenoﬁbrate 13 272.0 62.6 5 38.5
Fluvastatin 1 0 0.0
Lovastatin 1 0 0.0
Pravastatin 1 0 0.0
Undeﬁned statin 5 10.0 1 20.0
Low risk 111 12.4% Rosuvastatin 51 13.8 4.9 40 78.4
Atorvastatin 40 25.8 17.8 36 90.0
Simvastatin 12 21.0 11.0 10 83.3
Fenoﬁbrate 7 253.3 72.3 6 85.7
Ezetimibe 6 13.3 5.2 6 100.0
Fluvastatin 1 10.0 1 100.0
Lovastatin 1 40.0 1 100.0
Undeﬁned statin 5 20.0 12.2 5 100.0
Eighty-ﬁve patients were on combined-drug therapy. Each patient was on an average of 1.1 drugs
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Table 3 LDL-C target goal achievement according to EAS/ESC 2011 guidelines by different sample determinants
Determinant Variable Base Achieved Not achieved p value
Yes % No %
Reason for treatment Primary prevention 520 189 36.3 331 63.7 0.082
Secondary prevention 296 86 29.1 210 70.9
Familial hypercholesterolemia 60 23 38.3 37 61.7
Metabolic syndrome Metabolic syndrome 492 159 32.3 333 67.7 0.087
Non-metabolic syndrome 404 149 36.9 255 63.1
Gender Male 516 167 32.4 349 67.6 0.140
Female 380 141 37.1 239 62.9
Age distribution \20 years 1 0 0.0 1 100.0 0.081
20–34 years 40 21 52.5 19 47.5
35–39 years 39 19 48.7 20 51.3
40–44 years 89 34 38.2 55 61.8
45–49 years 132 45 34.1 87 65.9
50–54 years 170 60 35.3 110 64.7
55–59 years 163 50 30.7 113 69.3
60–64 years 122 32 26.2 90 73.8
65–69 years 85 26 30.6 59 69.4
70–74 years 33 15 45.5 18 54.5
75–79 years 10 3 30.0 7 70.0
[79 years 12 3 25.0 9 75.0
Ethnic origin Middle Eastern
(including North Africa)
857 297 34.7 560 65.3 0.135
Caucasian (including Europe
and North America)
6 1 16.7 5 83.3
Others 6 0 0.0 6 100.0
Current smoking Smokers 207 71 34.3 136 65.7 0.971
Non-smokers 665 229 34.4 436 65.6
Diabetes mellitus Diabetics 440 95 21.6 345 78.4 0.000
Non-diabetics 437 203 46.5 234 53.5
Arterial hypertension Arterial hypertension 561 166 29.6 395 70.4 0.000
Non-arterial hypertension 310 132 42.6 178 57.4
Family history of CVD History of CVD 272 91 33.5 181 66.5 0.643
No history of CVD 573 201 35.1 372 64.9
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Q1 For what proportion of patients do you set individual target cholesterol levels expressed as an actual number.
82 8 76.9 27.2
Q2 Which lab measures do you generally use to set individual target cholesterol levels. (Yes)
Q2 Total Cholesterol 90 0 70 77.8%
Q2 HDL-C 90 0 64 71.1%
Q2 LDL-C 90 0 85 94.4%
Q2 Triglycerides 90 0 67 74.4%
Q3 Do you utilize any guidelines to help establish individual cholesterol targets for your patients? (yes)
88 2 84 95.50%
Q4a) Which guidelines do you use? You can give more than one answer
* Joint European guidelines (SCORE) 29 61 12 41.4%
* NCEP ATP III guidelines (FRAMINGHAM) 29 61 13 44.8%
* National guidelines (if present) 29 61 7 24.1%
* Local healthcare authority 
guidelines/recommendations 29 61 3 10.3%
* Individual practice guidelines/recommendations 29 61 9 31.0%
* Other (write in) 29 61 0 0.0%
* Unable to name the precise guidelines used 29 61 0 0.0%
Q4b) Which one do you mainly use? Give only one answer
* Joint European guidelines (SCORE) 82 8 44 53.7%
* NCEP ATP III guidelines (FRAMINGHAM) 82 8 25 30.5%
* National guidelines (if present) 82 8 3 3.7%
* Local healthcare authority 
guidelines/recommendations 82 8 0 0.0%
* Individual practice guidelines/recommendations 82 8 6 7.3%
* Other (write in) 82 8 4 4.9%
* Unable to name the precise guidelines used 82 8 0 0.0%
Q5 When patients are first diagnosed with hypercholesterolemia do you generally inform them of their cholesterol 
level?
Yes Yes 83 98.8%
No No 1 1.2%
Q6 In what proportion of patients do you
Q6a) not mention extent of reduction at all 86 4 8.8 12.2
Q6b) provide a target cholesterol level expressed as an 
actual number 86 4 63.1 28.8
Q6c) provide a percentage or proportion reduction 86 4 14.8 15.3
Q6d) provide a more general description such as a 
need to reduce by ‘a little’ or ‘a lot’ 86 4 13.3 15.4
Q7 When informing your patients which of the following types of lipid parameters measurement do you generally 
use? You can give more than one answer (Yes)
Q7 Total cholesterol 88 2 70 79.5%
Q7 HDL-C 88 2 56 63.6%
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Table 4 continued
Q7 LDL-C 88 2 78 88.6%
Q7 Triglycerides 88 2 59 67.00%
Q8 Focusing now on pharmacological treatment for hypercholesterolemia, for what percentage of your patients do 
you recommend treatment with:
Q8a) Statins 88 2 86.85 12.6
Q8b) Fibrates 88 2 9.45 10.4
Q8c) Bile acid sequestrants 88 2 1.42 3.0
Q8d) Other 88 2 2.27 4.8
Q9 How frequent do you see the patient to review their cholesterol level?
Less frequent than once per year 88 2 1 1.1%
Once per year 88 2 3 3.4%
Once every 6 months 88 2 12 13.6%
Once every 3 months 88 2 58 65.9%
More frequent than once per 3 months 88 2 14 15.9%
Q21 In summary, thinking of all your hypercholesterolemia patients what percentages of those that have been set 
a target cholesterol level fall into the following categories?
Q21a) Reached their target cholesterol level and 
continue to stay at this level 85 5 55.6% 21.1%
Q21b) Generally stay at their target cholesterol level 
but their cholesterol is sometimes too high 85 5 18.8% 11.5%
Q21c) Reached their target cholesterol level in the past 
but have now lapsed 85 5 14.7% 10.0%
Q21d) Have never reached their target cholesterol level 84 6 10.8% 12.1%
Q22 In general, once a patient has reached their target cholesterol level after what length of time do you ask that 
patient to come back to review their hypercholesterolemia? (months)
One month 85 5 3 3.50%
2 months 85 5 7 8.20%
3 months 85 5 52 61.20%
6 months 85 5 22 25.90%
12 months 85 5 1 1.20%
Q23 What percentage of patients actually attends this review?
85 5 69.7% 19.9%
Q10-20 Please circle the most applicable number that meets how much you agree/disagree with each one (1 is 
disagree strongly and 5 is agree strongly).















Q10 I feel frustrated that I am 
not always able to effectively 
treat my patients with 
cardiovascular disorders
86 40.7% 16.3% 14.0% 11.6% 17.4% 2.49
Q11 I find it stressful trying to 
get my patients to their 
cholesterol targets
84 27.4% 14.3% 21.4% 16.7% 20.2% 2.88
Q12 I feel pressured to get 
patients to their target 
cholesterol levels
85 22.4% 14.1% 14.1% 20.0% 29.4% 3.20
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reaching their LDL-C treatment goals according
to international guidelines. Compared to the
CEPHEUS I survey that had been conducted in
Egypt between October 2010 and June 2011,
achievement of treatment goal was 32.5% (339
patients out of 1043) according to the NCEP ATP
III Updated 2004 guidelines [8]. CEPHEUS II in
Egypt showed a slight improvement in terms of
achieving treatment goals compared to CEPHEUS
I according to NCEP ATP III Updated 2004
guidelines, as 39.6% (355 out of 896) in
CEPHEUS II achieved their LDL-C treatment goal.
CEPHEUS surveys in other countries were
reported and the achievement was 57% in
combined Western European countries [9], 49%
for combined Asian countries [10], and 49.1%
in combined eight Asian countries (Korea, Tai-
wan, Thailand, Indonesia, Philippines,
Malaysia, Vietnam, Hong Kong SAR, and China)
[10]. The individual results were 52% for South
Africa [11], 49% for Greece [7], 83% for Hong
Kong [12], 50% for Taiwan [13], 31.3% for
Indonesia [14], and 53% for Thailand [15].
Our study (CEPHEUS II) showed that the
lowest target LDL-C goal achievements were
obtained with diabetes mellitus (21.6%), fol-
lowed by secondary prevention (29.1%), arterial
hypertension (29.6%), and metabolic syndrome
(32.3%). On the contrary to previous findings
from the CEPHEUS Pan-Asian survey, most of
our patients with diabetes mellitus and hyper-
tension did not achieve LDL goals. It is worth
mentioning that ezetimibe achieved LDL-C goal
with the highest percentage of 41.3% (63 out of
89 patients), in contrast to current knowledge
in the literature about statins.
Table 4 continued
Q13 A sufficient number of 
patients reach their target 
cholesterol levels
86 5.8% 4.7% 20.9% 31.4% 37.2% 3.90
Q14 I’m frustrated that the 
guidelines instruct me to 
advise lifestyle changes alone 
as first line therapy in all 
patients
86 38.4% 10.5% 23.3% 12.8% 15.0% 2.56
Q15 I’m frustrated that the 
guidelines instruct me to 
prescribe a low dose of lipid-
lowering drug to all patients 
and titrate upwards
86 37.2% 10.5% 20.9% 16.3% 15.1% 2.62
Q16 I tend to prescribe a lipid 
lowering drug only to patients 
who have proved they can 
adhere to diet and exercise 
change
85 49.4% 22.4% 10.6% 5.8% 11.8% 2.08
Q17 Patient compliance 
decreases if lipid lowering 
drugs take too long to have an 
effect
86 12.8% 10.5% 17.4% 34.9% 24.4% 3.48
Q18 I feel constrained to use 
less effective lipid lowering 
drugs first line
86 41.9% 20.9% 12.8% 10.4% 14.0% 2.34
Q19 Patients become 
concerned that their condition 
is more severe if their lipid 
lowering drug is titrated up
86 12.8% 17.5% 26.7% 22.1% 20.9% 3.21
Q20 Patients become 
concerned that their condition 
is more severe if their lipid 
lowering drug is frequently 
changed
86 7.0% 15.1% 20.9% 33.7% 23.3% 3.51
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S1 Have you ever heard or been told about bad cholesterol, otherwise known as LDL-C?
Yes 891 1 707 79.3%
No 134 15.0%
Don’t Know 50 5.6%
S2 Have you ever heard or been told about good cholesterol, otherwise known as HDL-C?
Yes 891 1 675 75.7%
No 161 18.0%
Don’t Know 56 6.3%
S3 When you were first told by your doctor that you had high cholesterol did your doctor tell you what your 
cholesterol level was?
Yes 892 0 740 83.00%
No 152 17.00%
S4 Did your doctor give you a target cholesterol level to aim for?
Yes 890 692 77.80%
No 198 22.20%
S4b Did your doctor give you a target cholesterol level to aim for?
* Only prescribe a tablet 890 2 106 11.9%
* Both advise lifestyle changes and prescribe 
a tablet? 733 82.3%
* Only advice you to change your lifestyle 
e.g. change your diet, stop smoking and/or 
do more exercise?
50 5.6%
* Neither advice lifestyle changes nor 
prescribes a tablet 2 0.2%
S5 As a first step when you were diagnosed with high cholesterol, did the doctor:
* Only prescribe a tablet 890 2 106 11.9%
* Both advise lifestyle changes and prescribe 
a tablet? 733 82.3%
* Only advice you to change your lifestyle 
e.g. change your diet, stop smoking and/or 
do more exercise?
50 5.6%
* Neither advice lifestyle changes nor 
prescribes a tablet 2 0.2%
S6 Which one of the following best describes the number of times your cholesterol lowering tablets has been 
changed since it was first prescribed?
* Still on the same tablet - go to Q8 890 2 106 11.9%
* Still on the same tablet but the dose has 
increased - continue 733 82.3%
* Have changed tablets once or twice (may 
include adding another tablet) - continue 50 5.6%
* Have changed tablets several times (may 
also include adding other tablets) - continue 2 0.2%
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Table 5 continued
S7 How did you feel about your cholesterol lowering tablets having to be changed i.e. having the dose of your 
tablets increased or taking a different tablets? 
a. Satisfied 892 0 249 27.9%
b. Concerned that your condition was now a 
‘serious illness’ 892 0
130 14.6%
c. No strong feelings 892 0 81 9.1%
d. Less motivated to keep taking your tablets 892
0
32 3.6%
e. Irritated at having to keep making 
changes 892 0
79 8.9%
f. Disappointed that treatment was not 
successful 892 0
41 4.6%
S8 I am satisfied with the level of information available to me about high cholesterol:
Agree 892 0 700 78.50%
Disagree 104 12%
Don’t know/not applicable 88 9.90%
S9 I am frustrated that I still do not know whether my tablets have been effective enough in lowering my 
cholesterol.
Agree 889 3 185 20.8%
Disagree 602 68.0%
Don’t know/not applicable 102 11.5%
S10 I always take my tablets to lower my cholesterol every day.
Agree 889 3 790 88.90%
Disagree 88 10%
Don’t know/not applicable 11 1.20%
S11 I stopped taking my tablets when my cholesterol level returned to normal.
Agree 889 155 17.4%
Disagree 690 78.0%
Don’t know/not applicable 44 4.9%
S12 Sometimes I forgot to take my cholesterol lowering tablets.
Agree 889 3 368 41.4%
Disagree 505 57.0%
Don’t know/not applicable 16 1.8%
S13 Approximately how often do you forget to take your cholesterol lowering tablets?
* Once a week 474 418 135 28.5%
* Once every two weeks 97 20.5%
* More than once a week 102 21.5%
* Once a month or less 140 29.5%
S14 How often do you think you can miss a tablet without affecting your cholesterol levels?
* Once a week 871 21 215 24.7%
* Once every two weeks 120 13.8%
* More than once a week 156 17.9%
* Once a month or less 380 43.6%
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Finally, this study was an observational
rather than interventional study, and as such, it
suffers from many limitations. Most of the
variables that may affect treatment goals were
considered; however, many variables were not
counted, such as differences in clinical practice
between study investigators, lifestyle, diet fac-
tors, adverse events, and socioeconomic status.
CONCLUSIONS
Statins are the most frequently used lipid-low-
ering drugs and have a significant impact on
achieving target LDL-C goals. As per the current
CEPHEUS II results, hypercholesterolemia is still
not being effectively managed in many at-risk
patients in Egypt. The majority of patients
enrolled in the study, all of whom were being
actively treated with lipid-lowering medication,
were considered at high risk of a cardiovascular
event; hypercholesterolemia was particularly
poorly managed in this group. Initiatives are
needed to improve physicians’ management of
these patients with more focus on their risk
profiles. Patient compliance to treatment is still
urgently needed.
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Table 5 continued
S15 Which of the following best describes your current situation?
* I have not reached my target cholesterol 
level 887 5
151 17.0%
* I'm not sure whether I have reached my 
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a. Satisfied 742 150 560 75.5%
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g. No strong feelings 609 283 176 28.9%
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Every 6 months 246 27.9%
More frequent than once every 3 months 149 16.9%
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Less often than once a year 20 2.3%
Do not have check-ups 7 0.8%
Don't know/ Can't remember 20 2.3%
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